{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:46:58Z","timestamp":1764002818652,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Dutch Ministry of Health, Welfare and Sport","doi-asserted-by":"publisher","award":["SP332770"],"award-info":[{"award-number":["SP332770"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: The aim of this study was to systematically assess Adverse Events Following Immunization (AEFI) among children following administration of the human papillomavirus (HPV) vaccine (Cervarix\u00ae) included in the Dutch National Immunization Program (NIP) and to characterize the pattern and recurrence risk of AEFI after HPV revaccination. Methods: A longitudinal cohort event monitoring study, using patient-reported outcomes was used among recipients of the HPV vaccine at 10 years of age. Data were available for 3063 children following the first HPV vaccination and for 2209 children following the second HPV vaccination. Results: The most commonly reported AEFI following HPV vaccination were injection site reactions\u2014reported by 46.5% of participants after the first dose and 31.9% after the second dose\u2014followed by headache (8.2% and 3.9%, respectively) and joint pain (4.5% and 3.7%, respectively). Participants who received both HPV vaccine doses reported more AEFI after the first dose than after the second. Among girls, 61.2% reported at least one AEFI following the first dose, compared to 44.2% after the second dose. For boys, these percentages were 55.3% and 38.5%, respectively. This difference was statistically significant (p = 0.002). For some AEFI, such as injection site reactions, there appears to be a potential increased risk of recurrence following the second dose. Conclusions: This prospective longitudinal cohort event monitoring study showed that AEFI were more frequent after the first HPV dose and more frequent for girls compared to boys. An increased risk of recurrence was seen for AEFI, such as injection site reactions and headache. Furthermore, this study provides insight into the course of AEFI and the extent to which children were affected by these symptoms based on real-world data.<\/jats:p>","DOI":"10.3390\/vaccines13080812","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:00:41Z","timestamp":1753884041000},"page":"812","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Frequency, Timing, Burden and Recurrence of Adverse Events Following Immunization After HPV Vaccine Based on a Cohort Event Monitoring Study in the Netherlands"],"prefix":"10.3390","volume":"13","author":[{"given":"Monika","family":"Raethke","sequence":"first","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Gorter","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Kalf","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-9434","authenticated-orcid":false,"given":"Leontine","family":"van Balveren","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Jajou","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"},{"name":"Department of PharmacoTherapy\u2014Epidemiology & Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Broerstraat 5, 9712 CP Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"ref_1","unstructured":"RIVM (2025, February 10). Rijksvaccinatieprogramma. Available online: https:\/\/rijksvaccinatieprogramma.nl\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.vaccine.2011.04.050","article-title":"Reported adverse events in girls aged 13-16 years aftervaccination with the human papillomavirus (HPV)-16\/18 vaccine in the Netherlands","volume":"29","author":"Kemmeren","year":"2011","journal-title":"Vaccine"},{"key":"ref_3","unstructured":"Gezondsheidsraad (2025, March 28). Vaccinatie Tegen HPV. Available online: https:\/\/www.gezondheidsraad.nl\/documenten\/adviezen\/2019\/06\/19\/vaccinatie-tegen-hpv."},{"key":"ref_4","unstructured":"RIVM (2025, March 31). Rijksvaccinatie Programma\u2014Onderbouwing en Wijzigingen in Historisch Overzicht. Available online: https:\/\/rijksvaccinatieprogramma.nl\/professionals\/richtlijnen\/uitvoering\/3-onderbouwing-en-wijzigingen."},{"key":"ref_5","unstructured":"RIVM (2025, March 31). Rijksvaccinatie Programma\u2014Vaccineren Tegen HPV. Available online: https:\/\/rijksvaccinatieprogramma.nl\/vaccinaties\/hpv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: A 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","unstructured":"RIVM (2025, June 02). More Than Two Million Invitations to Get Vaccinated Against HPV in 2023. Available online: https:\/\/www.rivm.nl\/en\/news\/more-than-two-million-invitations-to-get-vaccinated-against-hpv-in-2023."},{"key":"ref_8","unstructured":"(2025, July 23). Bijwerkingencentrum Lareb. Available online: https:\/\/www.lareb.nl\/pages\/over-lareb."},{"key":"ref_9","unstructured":"Harmark, L. (2025, July 23). Web-Based Intensive Monitoring; A Patient Based Pharmacovigilance Tool: Rijksuniversiteit Groningen. Available online: https:\/\/www.rug.nl\/news\/2012\/06\/22_harmark?lang=en."},{"key":"ref_10","unstructured":"RIVM (2025, July 23). Vaccinatieschema 2025. Available online: https:\/\/rijksvaccinatieprogramma.nl\/vaccinaties\/vaccinatieschema."},{"key":"ref_11","unstructured":"The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2025, July 23). Welcome to MedDRA. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_12","unstructured":"The Council for International Organizations of Medical Sciences (2025, July 23). CIOMS Current Challenges in Pharmacovigilance: Pragmatic Approaches. Report of CIOMS Working Group V. Available online: https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/Group5_Pharmacovigilance.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Laupeze","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12452-016-0060-z","article-title":"Postvaccinatie verschijnselen: Prikplaatsreacties en reactogeniciteit","volume":"48","year":"2016","journal-title":"JGZ Tijdschr. voor Jeugdgezondheidsz."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40780-017-0087-6","article-title":"Safety of human papillomavirus vaccines in healthy young women: A meta-analysis of 24 controlled studies","volume":"3","author":"Ogawa","year":"2017","journal-title":"J. Pharm. Heal. Care Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1016\/j.vaccine.2015.05.040","article-title":"Reactogenicity of trivalent inactivated influenza vaccine in young children: Pronounced reactions by previous successive vaccinations","volume":"33","author":"Okada","year":"2015","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/21645515.2017.1288328","article-title":"The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial","volume":"13","author":"Dai","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e12223","DOI":"10.2196\/12223","article-title":"Postvaccination Fever Response Rates in Children Derived Using the Fever Coach Mobile App: A Retrospective Observational Study","volume":"7","author":"Ahn","year":"2019","journal-title":"JMIR mHealth uHealth"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.contraception.2016.10.003","article-title":"Prescribing of cyproterone acetate\/ethinylestradiol in UK general practice: A retrospective descriptive study using The Health Improvement Network","volume":"95","author":"Soriano","year":"2017","journal-title":"Contraception"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40264-023-01356-7","article-title":"The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands","volume":"46","author":"Slingerland","year":"2023","journal-title":"Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Duijster, J.W., Lieber, T., Pacelli, S., Van Balveren, L., Ruijs, L.S., Raethke, M., Kant, A., and Van Hunsel, F. (2023). Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1078736"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cophys.2018.03.010","article-title":"The evolution of greater humoral immunity in females than males: Implications for vaccine efficacy","volume":"6","author":"Fink","year":"2018","journal-title":"Curr. Opin. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/trstmh\/tru167","article-title":"Sex-based differences in immune function and responses to vaccination","volume":"109","author":"Klein","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.vaccine.2024.03.025","article-title":"Adverse events following immunisation: Prospective cohort study evaluating Australian children presenting to specialist immunisation clinics","volume":"42","author":"Stubbs","year":"2024","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2022.07.019","article-title":"Revaccination and Adverse Event Recurrence in Patients with Adverse Events following Immunization","volume":"250","author":"MacDonald","year":"2022","journal-title":"J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.vaccine.2022.01.013","article-title":"COVID-19 vaccine reactogenicity\u2014A cohort event monitoring study in the Netherlands using patient reported outcomes","volume":"40","author":"Rolfes","year":"2022","journal-title":"Vaccine"},{"key":"ref_28","unstructured":"Centraal Bureau Voor de Statistiek (CBS) (2025, March 31). Wat Is Het Onderwijsniveau van Nederland?. Available online: https:\/\/longreads.cbs.nl\/nederland-in-cijfers-2024\/wat-is-het-onderwijsniveau-van-nederland\/."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/812\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:12Z","timestamp":1760033952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["vaccines13080812"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13080812","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}